Post by account_disabled on Mar 11, 2024 3:38:43 GMT -5
According to conclusions reached today by the EMA safety committee (PRAC), “unusual” blood clots with low platelets “should be included as very rare side effects” of the AstraZeneca vaccine , based on “all available evidence.” currently”, including the advice of a special group of experts. EMA experts have not been able to identify a risk factor for these events, such as age, sex or a previous medical history, although a “plausible explanation (for these rare cases of blood clotting) is that they are an immune response to the vaccine” in some people, so the PRAC has requested new studies to try to gather more information and take the necessary additional measures. The executive director of the EMA, Emer Cooke, stressed, in a telematic press conference from the agency's headquarters in Amsterdam, that covid-19 is a “very dangerous disease” and vaccines are “very important to fight against it.
Pandemic”, which includes AstraZeneca, which “has been shown to be highly effective” against the coronavirus. “The PRAC has confirmed that the benefits of the AstraZeneca vaccine in preventing Covid-19 generally outweigh the risks of side effects,” added Cooke, who reiterated that “after an in-depth Belgium Mobile Number List analysis, it has been concluded that that reported cases of unusual blood clots following vaccination should be included as possible side effects of the vaccine.” If it continues to recommend its use in the EU, it will decide whether to veto its use in certain groups defined by age, sex or medical history, considering that they could be at greater risk of developing blood clots. As there is no defined risk factor, the EMA emphasizes that it is “important that both vaccinated people and health professionals are aware of the possibility of developing very rare cases of blood clotting combined with low levels of platelets in blood within two weeks after vaccination.” So far most reported cases have occurred in women under 60 years of age within 15 days of vaccination.
The PRAC reviewed in depth a total of 62 cases of cerebral venous thrombus (CVST) and 24 cases of splanchnic vein thrombosis , reported up to March 22, of which 18 were fatal . For its part, the Portuguese presidency of the EU has called an extraordinary meeting of the health ministers of the bloc's countries at 6:00 p.m. to analyze the EMA report. The PRAC continued with the meeting that began yesterday to conclude its investigation into the very rare cases of thromboembolisms, after yesterday afternoon it had not yet reached a conclusion on the link of the vaccine with blood clotting. However, the head of the EMA's vaccine strategy, Marco Cavaleri, assured yesterday that there is a "clear" link between AstraZeneca and the very rare cases of blood clots, a conclusion that the EMA has not yet officially confirmed. Cavaleri commented to the Italian newspaper “Il Messaggero” that, in his opinion, “now we can say that it is clear that there is an association (of thrombi) with the vaccine, but we still do not know what causes this reaction”, detected in numerous vaccinated citizens.